Viatris (VTRS) Accounts Payables (2019 - 2026)
Viatris (VTRS) posted Accounts Payables of $1.7 billion for Q2 2026, down 1.31% on a QoQ basis from $1.7 billion in Q1 2026, and down 3.15% year-over-year from $1.8 billion in Q2 2025.
Analysis
Viatris (VTRS) Accounts Payables (2019 - 2026) Analysis & Trends
Viatris has reported Accounts Payables for 8 years, with the latest figure at $1.7 billion in Q2 2026.
- On a quarterly basis, Accounts Payables fell 3.15% year-over-year to $1.7 billion in Q2 2026; TTM through Jun 2026 was $1.7 billion, a 3.15% decrease from a year earlier, with the FY2025 full-year figure at $1.8 billion, down 5.37% from the prior year.
- Accounts Payables was $1.7 billion for Q2 2026 at Viatris, down from $1.7 billion in the prior quarter.
- The five-year high for Accounts Payables was $2.2 billion in Q1 2024, with the low at $1.3 billion in Q3 2022.
- Average Accounts Payables over 5 years is $1.8 billion, with a median of $1.8 billion recorded in 2024.
- The sharpest annual moves came in 2022 and 2023: Accounts Payables retreated 26.61% in 2022, then jumped 51.78% in 2023.
- Over 5 years, Accounts Payables stood at $1.8 billion in 2022, then climbed by 9.71% to $1.9 billion in 2023, then slipped by 4.36% to $1.9 billion in 2024, then decreased by 5.37% to $1.8 billion in 2025, then fell by 1.57% to $1.7 billion in 2026.
- The last three Accounts Payables figures came in at $1.7 billion (Q2 2026), $1.7 billion (Q1 2026), and $1.8 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.57 Bn | 38.91 Bn | 2.15 Bn | 2.72 Bn |
| 2 | Viatris | 19.20 Bn | 18.31 Bn | 1.46 Bn | 1.73 Bn |
| 3 | Dr Reddys Laboratories | 9.86 Bn | 9.69 Bn | 396.53 Mn | 396.07 Mn |
| 4 | Amneal Pharmaceuticals | 5.48 Bn | 5.35 Bn | 334.51 Mn | 721.21 Mn |
| 5 | Bausch Health Companies | 2.36 Bn | 520.75 Mn | 2.10 Bn | 593.00 Mn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | 133.16 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 73.83 Mn |
| 8 | Amphastar Pharmaceuticals | 995.52 Mn | 705.40 Mn | 93.47 Mn | 251.37 Mn |
| 9 | Fennec Pharmaceuticals | 406.25 Mn | 365.00 Mn | 17.15 Mn | 5.52 Mn |
| 10 | RedHill Biopharma | 176.59 Mn | 176.59 Mn | - | 731,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.73 Bn |
| Mar 31, 2026 | 1.75 Bn |
| Dec 31, 2025 | 1.75 Bn |
| Sep 30, 2025 | 1.79 Bn |
| Jun 30, 2025 | 1.78 Bn |
| Mar 31, 2025 | 1.99 Bn |
| Dec 31, 2024 | 1.85 Bn |
| Sep 30, 2024 | 1.93 Bn |
| Jun 30, 2024 | 1.96 Bn |
| Mar 31, 2024 | 2.20 Bn |
| Dec 31, 2023 | 1.94 Bn |
| Sep 30, 2023 | 1.99 Bn |
| Jun 30, 2023 | 1.96 Bn |
| Mar 31, 2023 | 1.96 Bn |
| Dec 31, 2022 | 1.77 Bn |
| Sep 30, 2022 | 1.31 Bn |
| Jun 30, 2022 | 1.67 Bn |
| Mar 31, 2022 | 1.50 Bn |
| Dec 31, 2021 | 1.66 Bn |
| Sep 30, 2021 | 1.66 Bn |